Praktické lékárenství – 4/2020

www.praktickelekarenstvi.cz e12 MEDICAMENTA NOVA Nová přímá perorální antikoagulancia –nové molekuly ve výzkumu PRAKTICKÉ LÉKÁRENSTVÍ ps://linkinghub.elsevier.com/retrieve/pii/S0140673609614549 24. Dillinger J‑G, Gregory DUCROCQ, Elbez Y, et al. Activated Clotting Time to Guide Hepa- rin Dosing in Non–ST‑Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. Circulation: Cardi- ovascular Interventions [online]. 2018, 11(6) [cit. 2019–03–26]. DOI: 10.1161/CIRCINTERVEN- TIONS.118.006084. ISSN 1941-7640. Dostupné z: https://www.ahajournals.org/doi/10.1161/ CIRCINTERVENTIONS.118.006084 25. Deharo P, Ducrocq G, Bode CH, et al. Timing of Angiography and Outcomes in High­ ‑Risk Patients With Non–ST‑Segment–Elevation Myocardial Infarction Managed Invasive- ly. Circulation [online]. 2017, 136(20), 1895–1907 [cit. 2019–03–26]. DOI: 10.1161/CIRCULATI- ONAHA.117.029779. ISSN 0009-7322. Dostupné z: https://www.ahajournals.org/doi/10.1161/ CIRCULATIONAHA.117.029779 26. Steg PG. Anticoagulation With Otamixaban and Ischemic Events in Non–ST‑Segment Elevation Acute Coronary Syndromes. JAMA [online]. 2013, 310(11) [cit. 2019–03–26]. DOI: 10.1001/jama.2013.277165. ISSN 0098-7484. Dostupné z: http://jama.jamanetwork.com/ar- ticle.aspx?doi=10.1001/jama.2013.277165 27. Dhakal P. Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. Clinical and Applied Thrombosis/ Hemostasis [online]. 2016, 23(5), 410–415 [cit. 2019–03–27]. DOI: 10.1177/1076029616675970. ISSN 1076-0296. Dostupné z: http://journals.sagepub.com/doi/10.1177/1076029616675970 28. Levy JH, Douketis J, Weitz JI. Reversal agents for non‑vitamin K antagonist oral anti- coagulants. Nature Reviews Cardiology [online]. 2018, 15(5), 273–281 [cit. 2019–03–27]. DOI: 10.1038/nrcardio.2017.223. ISSN 1759-5002. Dostupné z: http://www.nature.com/doifin- der/10.1038/nrcardio.2017.223 29. Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anti- coagulants? Kardiologia Polska [online]. 2019, 77(1), 3–11 [cit. 2019–03–27]. DOI: 10.5603/ KP.a2018.0197. ISSN 1897-4279. Dostupné z: https://ojs.kardiologiapolska.pl/kp/article/ view/12634 30. Ansell JE, Bakhru SH, Laulicht BE, et al. Single‑dose ciraparantag safely and complete- ly reverses anticoagulant effects of edoxaban. Thrombosis and Haemostasis [online]. 2017, 117(02), 238–245 [cit. 2019–03–27]. DOI: 10.1160/TH16–03–0224. ISSN 0340-6245. Dostupné z: http://www.thieme‑connect.de/DOI/DOI?10.1160/TH16–03–0224 31. Dabi A, Koutrouvelis AP. Reversal Strategies for Intracranial Hemorrhage Related to Di- rect Oral Anticoagulant Medications. Critical Care Research and Practice [online]. 2018, 2018, 1–11 [cit. 2019–03–27]. DOI: 10.1155/2018/4907164. ISSN 2090-1305. Dostupné z: htt- ps://www.hindawi.com/journals/ccrp/2018/4907164/ 32. Riley TR, Gauthier‑Lewis ML, Sanchez CHK, DOUGLAS JS. Role of agents for reversing the effects of target‑specific oral anticoagulants. American Journal of Health‑System Phar- macy [online]. 2017, 74(2), 54–61 [cit. 2019–03–27]. DOI: 10.2146/ajhp150810. ISSN 1079-2082. Dostupné z: https://academic.oup.com/ajhp/article/74/2/54/5102888